| Literature DB >> 29109690 |
Jingyu Shi1,2, Lu Wang1, Yuhong Yao3, Na Su2, Chenyu Zhan1, Ziyu Mao1, Xudong Zhao1,2.
Abstract
BACKGROUND: High rates of non-psychotic psychopathological symptoms have been observed in clinical population at clinical high risk (CHR) for psychosis. These comorbid disorders affected the baseline functional level of CHR patients. However, little is known about the comorbid mental disorder in CHR individuals in non-clinical adolescent population. This study aimed to investigate the comorbid mental disorder in non-clinical CHR adolescents and the impact on attenuated psychosis symptoms (APS) as well as clinical outcome.Entities:
Keywords: anxiety; clinical high risk; depression; longitudinal; psychosis; university students
Year: 2017 PMID: 29109690 PMCID: PMC5660058 DOI: 10.3389/fpsyt.2017.00209
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Inclusion and exclusion criteria for CHR.
| Inclusion criteria | Exclusion criteria |
|---|---|
Age between 16 and 30 years Presence of at least one of the following criteria based on SIPS APSS BIPS GRDS | Any history of the following disorders: Schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, bipolar disorder. Somatic disorder-induced mental disorder, psychoactive substance-induced mental disorder. Substance abuse Organic brain damage, epilepsy Continuously taking antipsychotic drugs, antidepressants and emotional stabilizers for more than 2 weeks over the past 3 months |
APSS, Attenuated Positive Symptom Prodromal Syndrome; BIPS, Brief Intermittent Psychosis Prodromal Syndrome; CHR, clinical high risk; GRDS, Genetic Risk and Deterioration Prodromal Syndrome; SIPS, Structured Interview for Psychosis-Risk Syndromes.
Baseline-attenuated psychotic characteristics.
| Item | Mean ± SD | Median (Q1, Q3) | ||
|---|---|---|---|---|
| Positive symptoms | 32 (100.0) | 7.81 ± 3.542 | 7.00 (4.25, 10.00) | |
| P1 | Unusual thought content/delusional ideas | 18 (56.3) | 2.38 ± 1.621 | 3.00 (1.00, 4.00) |
| P2 | Suspiciousness/persecutory ideas | 6 (18.8) | 1.34 ± 1.558 | 1.00 (0.00, 2.00) |
| P3 | Grandiose ideas | 2 (6.3) | 0.50 ± 0.950 | 0.00 (0.00, 1.00) |
| P4 | Perceptual abnormalities/hallucinations | 28 (87.5) | 2.88 ± 1.040 | 3.00 (3.00, 3.00) |
| P5 | Disorganized communication | 1 (3.1) | 0.72 ± 0.991 | 0.00 (0.00, 1.00) |
| Negative symptoms | 10 (31.3) | 5.16 ± 5.100 | 4.00 (1.00, 8.75) | |
| N1 | Social anhedonia | 6 (18.8) | 1.34 ± 1.473 | 1.00 (0.00, 2.00) |
| N2 | Avolition | 3 (9.4) | 0.88 ± 1.212 | 0.00 (0.00, 1.75) |
| N3 | Expression of emotion | 5 (15.6) | 0.84 ± 1.221 | 0.00 (0.00, 1.75) |
| N4 | Experience of emotions and self | 5 (15.6) | 1.00 ± 1.136 | 1.00 (0.00, 2.00) |
| N5 | Ideational richness | 0 (0.0) | 0.28 ± 0.634 | 0.00 (0.00, 0.00) |
| N6 | Occupational functioning | 1 (3.1) | 0.81 ± 0.965 | 0.00 (0.00, 1.00) |
| Disorganized symptoms | 7 (21.9) | 2.97 ± 2.935 | 2.00 (0.25, 4.75) | |
| D1 | Odd behavior of appearance | 1 (3.1) | 0.50 ± 0.984 | 0.00 (0.00, 0.75) |
| D2 | Bizarre thinking | 7 (21.9) | 1.09 ± 1.254 | 0.50 (0.00, 2.00) |
| D3 | Trouble with focus and attention | 3 (9.4) | 1.31 ± 1.091 | 1.50 (0.00, 2.00) |
| D4 | Impairment in personal hygiene | 0 (0.0) | 0.00 ± 0.246 | 0.00 (0.00,0.00) |
| General symptoms | 8 (25.0) | 3.50 ± 2.828 | 3.50 (1.00, 5.75) | |
| G1 | Sleep disturbance | 4 (12.5) | 0.84 ± 1.221 | 0.00 (0.00, 2.00) |
| G2 | Dysphoric mood | 5 (15.6) | 1.25 ± 1.244 | 1.00 (0.00, 2.00) |
| G3 | Motor disturbances | 0 (0.0) | 0.47 ± 0.671 | 0.00 (0.00, 1.00) |
| G4 | Impaired tolerance to normal stress | 1 (3.1) | 0.94 ± 0.914 | 1.00 (0.00, 2.00) |
| GAF | 71.53 ± 7.392 | 73.50 (68.50, 78.00) | ||
.
GAF, Global Assessment of Functioning.
Distribution of comorbid psychopathology in CHR individuals.
| Comorbid psychopathology | |
|---|---|
| Generalized anxiety disorder | 8 (25) |
| Social phobia | 6 (18.8) |
| Obsessive-compulsive Disorder | 4 (12.5) |
| Panic attack | 3 (9.4) |
| Agoraphobia | 3 (9.4) |
| Specific phobia | 3 (9.4) |
| Depression | 3 (9.4) |
| Dysthymia | 3 (9.4) |
| Somatization disorder | 1 (3.1) |
| Body dysmorphic disorder | 1 (3.1) |
CHR, clinical high risk.
Severity of attenuated psychotic symptoms and GAF in two groups (x ± SD).
| Group with CPS ( | Group without CPS ( | |||
|---|---|---|---|---|
| PS | 9.13 ± 2.924 | 6.65 ± 3.707 | −2.086 | 0.046 |
| NS | 7.13 ± 5.423 | 3.41 ± 4.214 | −2.181 | 0.037 |
| DS | 3.67 ± 3.155 | 2.35 ± 2.668 | −1.276 | 0.212 |
| GS | 4.60 ± 2.823 | 2.53 ± 2.528 | −2.189 | 0.036 |
| GAF | 70.47 ± 8.935 | 72.47 ± 5.832 | 0.760 | 0.453 |
CPS, comorbid psychopathological symptoms; DS, disorganized symptoms; GAF, Global Assessment of Functioning; GS, general symptoms; PS, positive symptoms; NS, negative symptoms.